Veno-Venous Extracorporeal Membrane Oxygenation in Adult Patients with Sickle Cell Disease and Acute Chest Syndrome: a Single-Center Experience. (3rd March 2020)

• Record Type: Journal Article
• Authors: Alashkar, Ferras; Herbstreit, Frank; Carpinteiro, Alexander; Baum, Julia; Tzalavras, Asterios; Aramayo-Singelmann, Carmen; Vance, Colin; Lenz, Veronika; Gulbins, Erich; Reinhardt, Dirk; Beelen, Dietrich W.; Dührsen, Ulrich; Röth, Alexander; Koldehoff, Michael; Liebregts, Tobias
• Is Part Of: Hemoglobin. Volume 44:Number 2(2020)
• Page Start: 71
• Page End: 77
• Publication Date: 2020-03-03
• Subjects: Acute chest syndrome (ACS) -- sickle cell disease -- extracorporeal membrane oxygenation (ECMO); Hemoglobinopathy -- Periodicals; Hemoglobin -- Periodicals; Hematology -- Periodicals; Thalassemia -- Periodicals; Blood -- Diseases -- Periodicals; 612.1111
• DOI: 10.1080/03630269.2020.1745827
• Languages: English
• ISSNs: 0363-0269

Abstract

Abstract: Acute chest syndrome (ACS) in adult patients with sickle cell disease represents a leading cause of death. It is characterized by a new density on chest X-ray accompanied by fever and/or respiratory symptoms. Currently, 49 adult patients with sickle cell disease are registered at our department. By now, 12 patients (24.5%) suffered from ACS and two patients showed multiple/recurrent (>2) episodes. Death in one patient was related to acute respiratory failure secondary to ACS. In three patients with ACS, invasive mechanical ventilation and subsequent veno-venous extracorporeal membrane oxygenation (VV-ECMO) was mandatory. Veno-venous ECMO was applied within 24 hours upon arrival to the intensive care unit (ICU). All patients were treated aggressively for ACS including exchange transfusions [packed red blood cell (pRBC) units 5–16] maintaining a Hb S threshold of <30.0% in addition to broad-spectrum antibiotics, resulting in a successful outcome following decannulation from VV-ECMO (49 hours, 251 hours, 30 min., and 98 hours, respectively). Limited information is presently available on the use of VV-ECMO in adult patients with sickle cell disease in the context of acute respiratory failure secondary to ACS. The adequate timing of the decision to place ECMO in critically ill adults with sickle cell disease, incapable of being treated by conventional mechanical ventilation secondary to very severe vaso-occlusive crisis (VOC), might further reduce mortality rates while treating the underlying condition.